Interestingly, in animal models, topical skin application of HDAC inhibitors significantly suppressed cutaneous side effects of radiotherapy [41], suggesting that the contemporary approach of molecularly targeted therapy may be utilized to increase the therapeutic ratio between the tumor and surrounding normal tissues in radiotherapy. Here, HDAC9 is linked to neoplasm.